vs

Side-by-side financial comparison of CuriosityStream Inc. (CURI) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $19.2M, roughly 1.9× CuriosityStream Inc.). CuriosityStream Inc. runs the higher net margin — -19.7% vs -304.2%, a 284.5% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 35.8%). CuriosityStream Inc. produced more free cash flow last quarter ($3.9M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 26.5%).

Curiosity Stream Inc., formerly branded as CuriosityStream, is an American media company and over-the-top subscription video streaming service which offers documentary programming including films, series, and TV shows. The company offers a video on demand subscription service branded as "Curiosity Stream" and a linear broadcast television channel known as the Curiosity Channel through various services including FuboTV and The Roku Channel.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

CURI vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.9× larger
RXRX
$35.5M
$19.2M
CURI
Growing faster (revenue YoY)
RXRX
RXRX
+645.9% gap
RXRX
681.7%
35.8%
CURI
Higher net margin
CURI
CURI
284.5% more per $
CURI
-19.7%
-304.2%
RXRX
More free cash flow
CURI
CURI
$51.3M more FCF
CURI
$3.9M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
26.5%
CURI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CURI
CURI
RXRX
RXRX
Revenue
$19.2M
$35.5M
Net Profit
$-3.8M
$-108.1M
Gross Margin
59.8%
Operating Margin
-17.6%
-304.8%
Net Margin
-19.7%
-304.2%
Revenue YoY
35.8%
681.7%
Net Profit YoY
-34.6%
39.6%
EPS (diluted)
$-0.07
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CURI
CURI
RXRX
RXRX
Q4 25
$19.2M
$35.5M
Q3 25
$18.4M
$5.2M
Q2 25
$19.0M
$19.2M
Q1 25
$15.1M
$14.7M
Q4 24
$14.1M
$4.5M
Q3 24
$12.6M
$26.1M
Q2 24
$12.4M
$14.4M
Q1 24
$12.0M
$13.8M
Net Profit
CURI
CURI
RXRX
RXRX
Q4 25
$-3.8M
$-108.1M
Q3 25
$-3.7M
$-162.3M
Q2 25
$784.0K
$-171.9M
Q1 25
$319.0K
$-202.5M
Q4 24
$-2.8M
$-178.9M
Q3 24
$-3.1M
$-95.8M
Q2 24
$-2.0M
$-97.5M
Q1 24
$-5.0M
$-91.4M
Gross Margin
CURI
CURI
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
CURI
CURI
RXRX
RXRX
Q4 25
-17.6%
-304.8%
Q3 25
-24.5%
-3327.6%
Q2 25
2.5%
-916.8%
Q1 25
0.5%
-1297.9%
Q4 24
-27.4%
-4042.4%
Q3 24
-25.8%
-377.1%
Q2 24
-20.6%
-697.4%
Q1 24
-30.4%
-698.4%
Net Margin
CURI
CURI
RXRX
RXRX
Q4 25
-19.7%
-304.2%
Q3 25
-20.4%
-3135.3%
Q2 25
4.1%
-894.2%
Q1 25
2.1%
-1373.3%
Q4 24
-19.9%
-3935.5%
Q3 24
-24.3%
-367.5%
Q2 24
-16.4%
-676.6%
Q1 24
-42.0%
-662.4%
EPS (diluted)
CURI
CURI
RXRX
RXRX
Q4 25
$-0.07
$-0.17
Q3 25
$-0.06
$-0.36
Q2 25
$0.01
$-0.41
Q1 25
$0.01
$-0.50
Q4 24
$-0.05
$-0.56
Q3 24
$-0.06
$-0.34
Q2 24
$-0.04
$-0.40
Q1 24
$-0.09
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CURI
CURI
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$27.3M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$41.5M
$1.1B
Total Assets
$75.7M
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CURI
CURI
RXRX
RXRX
Q4 25
$27.3M
$743.3M
Q3 25
$27.8M
$659.8M
Q2 25
$28.1M
$525.1M
Q1 25
$33.4M
$500.5M
Q4 24
$32.1M
$594.4M
Q3 24
$33.2M
$427.6M
Q2 24
$39.5M
$474.3M
Q1 24
$38.8M
$296.3M
Total Debt
CURI
CURI
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
CURI
CURI
RXRX
RXRX
Q4 25
$41.5M
$1.1B
Q3 25
$47.2M
$1.0B
Q2 25
$49.8M
$919.1M
Q1 25
$58.1M
$933.9M
Q4 24
$57.8M
$1.0B
Q3 24
$62.2M
$524.6M
Q2 24
$64.8M
$584.4M
Q1 24
$67.0M
$401.2M
Total Assets
CURI
CURI
RXRX
RXRX
Q4 25
$75.7M
$1.5B
Q3 25
$74.7M
$1.4B
Q2 25
$78.7M
$1.3B
Q1 25
$85.3M
$1.3B
Q4 24
$86.2M
$1.4B
Q3 24
$87.6M
$726.5M
Q2 24
$90.9M
$775.9M
Q1 24
$94.6M
$557.8M
Debt / Equity
CURI
CURI
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CURI
CURI
RXRX
RXRX
Operating Cash FlowLast quarter
$4.0M
$-46.1M
Free Cash FlowOCF − Capex
$3.9M
$-47.3M
FCF MarginFCF / Revenue
20.5%
-133.1%
Capex IntensityCapex / Revenue
0.1%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CURI
CURI
RXRX
RXRX
Q4 25
$4.0M
$-46.1M
Q3 25
$4.4M
$-117.4M
Q2 25
$2.8M
$-76.4M
Q1 25
$1.9M
$-132.0M
Q4 24
$3.0M
$-115.4M
Q3 24
$2.3M
$-59.2M
Q2 24
$2.2M
$-82.2M
Q1 24
$666.0K
$-102.3M
Free Cash Flow
CURI
CURI
RXRX
RXRX
Q4 25
$3.9M
$-47.3M
Q3 25
$-117.6M
Q2 25
$-79.6M
Q1 25
$1.8M
$-133.8M
Q4 24
$-116.7M
Q3 24
$-63.8M
Q2 24
$-83.4M
Q1 24
$-109.0M
FCF Margin
CURI
CURI
RXRX
RXRX
Q4 25
20.5%
-133.1%
Q3 25
-2272.5%
Q2 25
-413.9%
Q1 25
12.2%
-907.4%
Q4 24
-2567.7%
Q3 24
-244.6%
Q2 24
-578.5%
Q1 24
-789.9%
Capex Intensity
CURI
CURI
RXRX
RXRX
Q4 25
0.1%
3.5%
Q3 25
0.0%
4.7%
Q2 25
0.0%
16.4%
Q1 25
0.5%
12.4%
Q4 24
0.0%
28.6%
Q3 24
0.0%
17.5%
Q2 24
0.0%
8.2%
Q1 24
0.0%
48.2%
Cash Conversion
CURI
CURI
RXRX
RXRX
Q4 25
Q3 25
Q2 25
3.56×
Q1 25
6.03×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons